» Articles » PMID: 12202012

Isradipine Enhancement of Cerebral Blood Flow in Abstinent Cocaine Abusers with and Without Chronic Perfusion Deficits

Overview
Journal Am J Addict
Specialty Psychiatry
Date 2002 Aug 31
PMID 12202012
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Nine cocaine abusers with cerebral blood flow (CBF) deficits (hypo-perfused areas) on HMPAO SPECT scans were compared to six without these deficits after six doses of isradipine (5 mg TID). When comparing the scan before isradipine to that after using SPM analysis, the ratio of hypo- to hyper-fusion showed a 16% increase in the maximum Z scores and 30% fewer areas of hypo-perfusion among those cocaine abusers with deficits. These deficits may represent segmental cerebral vasospasm that was reversed by this vasodilating agent in cocaine abusers with areas of hypo-perfusion (deficits) as baseline.

Citing Articles

Applications of isradipine in human addiction studies: A systematic literature review.

Natal S, Young C, Kaur K, Gebhardt E, Perrone A, Morikawa H Exp Clin Psychopharmacol. 2023; 31(2):507-522.

PMID: 36595455 PMC: 10152997. DOI: 10.1037/pha0000633.


Usage of L-type calcium channel blockers to suppress drug reward and memory driving addiction: Past, present, and future.

Morikawa H, Young C, Smits J Neuropharmacology. 2022; 221:109290.

PMID: 36241085 PMC: 10476140. DOI: 10.1016/j.neuropharm.2022.109290.


Cocaine promotes oxidative stress and microglial-macrophage activation in rat cerebellum.

Lopez-Pedrajas R, Ramirez-Lamelas D, Muriach B, Sanchez-Villarejo M, Almansa I, Vidal-Gil L Front Cell Neurosci. 2015; 9:279.

PMID: 26283916 PMC: 4516895. DOI: 10.3389/fncel.2015.00279.


Novel approaches to the treatment of cocaine addiction.

Sofuoglu M, Kosten T CNS Drugs. 2005; 19(1):13-25.

PMID: 15651902 DOI: 10.2165/00023210-200519010-00002.


Agents in development for the management of cocaine abuse.

Gorelick D, Gardner E, Xi Z Drugs. 2004; 64(14):1547-73.

PMID: 15233592 DOI: 10.2165/00003495-200464140-00004.